Drug Profile
Research programme: peptidomimetics - PDC Biotech
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator PDC Biotech
- Class Peptides
- Mechanism of Action Prostaglandin F antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Dysmenorrhoea
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Dysmenorrhoea in Austria (PO)
- 15 May 2008 Preclinical trials in Dysmenorrhoea in Austria (PO)